ERBB2 and breast carcinoma: The identification of the various causes for the immunosuppression and discovery of various molecules and TAAs (HER2, carbohydrate antigens, telomerase reverse transcriptase (hTERT), and mucin-1 (MUC-1)) led to the development of various strategies for the treatment of breast cancers by activating the immune system [46].